Glomerulonephritis - Pipeline Review, H2 2016

Date: September 14, 2016
Pages: 124
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G53DA23E3B0EN
Leaflet:

Download PDF Leaflet

Glomerulonephritis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Glomerulonephritis - Pipeline Review, H2 2016’, provides an overview of the Glomerulonephritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Glomerulonephritis
  • The report reviews pipeline therapeutics for Glomerulonephritis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Glomerulonephritis therapeutics and enlists all their major and minor projects
  • The report assesses Glomerulonephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Glomerulonephritis
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Glomerulonephritis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glomerulonephritis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Glomerulonephritis Overview
Therapeutics Development
Pipeline Products for Glomerulonephritis - Overview
Pipeline Products for Glomerulonephritis - Comparative Analysis
Glomerulonephritis - Therapeutics under Development by Companies
Glomerulonephritis - Therapeutics under Investigation by Universities/Institutes
Glomerulonephritis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Glomerulonephritis - Products under Development by Companies
Glomerulonephritis - Products under Investigation by Universities/Institutes
Glomerulonephritis - Companies Involved in Therapeutics Development
Achillion Pharmaceuticals, Inc.
Alexion Pharmaceuticals Inc
Amyndas Pharmaceuticals LLC
Anthera Pharmaceuticals Inc
Avexxin AS
Biogen Inc
Complexa, Inc.
Dimerix Bioscience Pty Ltd
GlaxoSmithKline Plc
Mallinckrodt Plc
Omeros Corporation
Pfizer Inc.
Pharmalink AB
Retrophin Inc.
Rigel Pharmaceuticals, Inc.
Shire Plc
Toray Industries, Inc.
Variant Pharmaceuticals, Inc.
Glomerulonephritis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(irbesartan + propagermanium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACH-4471 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMY-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
blisibimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
budesonide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CXA-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fostamatinib disodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
losmapimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Glycoprotein Ib Alpha for Vasculitis and Glomerulonephritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-721 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-1355 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Enzyme for Immunoglobulin A Nephropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHP-627 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Vitamin K Epoxide Reductase for Glomerulonephritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sparsentan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-5484 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAR-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glomerulonephritis - Dormant Projects
Glomerulonephritis - Discontinued Products
Glomerulonephritis - Product Development Milestones
Featured News & Press Releases
Aug 01, 2016: Dimerix announces outcomes of DMX-200 pre-IND meeting with the FDA
May 17, 2016: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Rare Cause of Nephrotic Syndrome
Mar 30, 2016: Retrophin Completes Enrollment of Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis
Mar 04, 2016: Amyndas’ lead candidate AMY-101 receives orphan drug status from the FDA and the EMA for the treatment of C3 glomerulopathy
Dec 14, 2015: Dimerix receives Orphan Designation for its lead drug candidate targeting patients with chronic kidney disease
Nov 16, 2015: Retrophin Receives European Orphan Drug Designation for Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
Jan 09, 2015: Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan
Feb 25, 2013: Ligand Receives $1.4m Milestone Payment From Retrophin
Jan 09, 2013: Ligand Receives Equity Milestone Payment From Retrophin
Oct 31, 2012: Pharmalink Signs Manufacturing Agreement For Nefecon
Oct 13, 2010: Pharmalink Receives US Orphan Drug Designation For Nefecon
Oct 26, 2009: Japanese Patent granted for Pharmalink AB's Nefecon
Apr 29, 2009: Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon
Mar 31, 2008: Pharmalink Reports Promising Interim Results From Phase II Trials For New Renal Disease Drug Nefecon
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 124

LIST OF TABLES

Number of Products under Development for Glomerulonephritis, H2 2016
Number of Products under Development for Glomerulonephritis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Glomerulonephritis - Pipeline by Achillion Pharmaceuticals, Inc., H2 2016
Glomerulonephritis - Pipeline by Alexion Pharmaceuticals Inc, H2 2016
Glomerulonephritis - Pipeline by Amyndas Pharmaceuticals LLC, H2 2016
Glomerulonephritis - Pipeline by Anthera Pharmaceuticals Inc, H2 2016
Glomerulonephritis - Pipeline by Avexxin AS, H2 2016
Glomerulonephritis - Pipeline by Biogen Inc, H2 2016
Glomerulonephritis - Pipeline by Complexa, Inc., H2 2016
Glomerulonephritis - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016
Glomerulonephritis - Pipeline by GlaxoSmithKline Plc, H2 2016
Glomerulonephritis - Pipeline by Mallinckrodt Plc, H2 2016
Glomerulonephritis - Pipeline by Omeros Corporation, H2 2016
Glomerulonephritis - Pipeline by Pfizer Inc., H2 2016
Glomerulonephritis - Pipeline by Pharmalink AB, H2 2016
Glomerulonephritis - Pipeline by Retrophin Inc., H2 2016
Glomerulonephritis - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016
Glomerulonephritis - Pipeline by Shire Plc, H2 2016
Glomerulonephritis - Pipeline by Toray Industries, Inc., H2 2016
Glomerulonephritis - Pipeline by Variant Pharmaceuticals, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Glomerulonephritis - Dormant Projects, H2 2016
Glomerulonephritis - Dormant Projects (Contd..1), H2 2016
Glomerulonephritis - Discontinued Products, H2 2016 113

LIST OF FIGURES

Number of Products under Development for Glomerulonephritis, H2 2016
Number of Products under Development for Glomerulonephritis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Otitis Media - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 86 pages

Ask Your Question

Glomerulonephritis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: